Park, M., Nam, J. S., Kim, T., Yoon, G., Kim, S., Lee, C., Lee, C. G., Park, S., Bejoymohandas, K. S., Yang, J., Kwon, Y. H., Lee, Y. J., Seo, J. K., Min, D., Park, T., & Kwon, T. (2024). Rational Design of Biocompatible Ir(III) Photosensitizer to Overcome Drug‐Resistant Cancer via Oxidative Autophagy Inhibition. Advanced Science. Portico. https://doi.org/10.1002/advs.202407236

Jeong, M.-S., Baek, S.-W., Yang, G.-E., Mun, J.-Y., Kim, J. A., Kim, T.-N., Nam, J.-K., Choi, Y.-H., Lee, J.-S., Chu, I.-S., & Leem, S.-H. (2025). Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters, 610, 217339. https://doi.org/10.1016/j.canlet.2024.217339

Kabeer, F., Tran, H., Andronescu, M., Singh, G., Lee, H., Salehi, S., Wang, B., Biele, J., Brimhall, J., Gee, D., Cerda, V., O’Flanagan, C., Algara, T., Kono, T., Beatty, S., Zaikova, E., Lai, D., Lee, E., … Moore, R. (2024). Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers. Genome Biology, 25(1). https://doi.org/10.1186/s13059-024-03318-3

Tai, Y., Chow, A., Han, S., Coker, C., Ma, W., Gu, Y., Estrada Navarro, V., Kandpal, M., Hibshoosh, H., Kalinsky, K., Manova-Todorova, K., Safonov, A., Walsh, E. M., Robson, M., Norton, L., Baer, R., Merghoub, T., Biswas, A. K., & Acharyya, S. (2024). FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Molecular Medicine, 16(8), 1957–1980. https://doi.org/10.1038/s44321-024-00094-2

Rosenberger, G., Li, W., Turunen, M., He, J., Subramaniam, P. S., Pampou, S., Griffin, A. T., Karan, C., Kerwin, P., Murray, D., Honig, B., Liu, Y., & Califano, A. (2024). Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47957-3

Cheng, Y. L., Banu, M. A., Zhao, W., Rosenfeld, S. S., Canoll, P., & Sims, P. A. (2024). Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma. Cell Reports, 43(5), 114139. https://doi.org/10.1016/j.celrep.2024.114139

Lenis, A. T., Whiting, K., Ravichandran, V., Tallman, J. E., Alam, S. M., Chu, C. E., Jesus Escano, M. D., Bochner, E., Katims, A., Reisz, P. A., Truong, H., Clinton, T. N., Telis, L., Dason, S., McPherson, V., Teo, M. Y., Funt, S., Aggen, D., Goh, A. C., … Pietzak, E. J. (2024). Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer. JCO Precision Oncology, 8. https://doi.org/10.1200/po.23.00274

Zhou, N., Choi, J., Grothusen, G., Kim, B.-J., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A., Beer, T., Tang, H.-Y., Perkey, E., Maillard, I., Bonasio, R., Shi, J., Ruella, M., Wan, L., & Busino, L. (2023). DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood, 142(11), 973–988. https://doi.org/10.1182/blood.2022018752